$Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen$

Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen

Treatment for relapsed/refractory multiple myeloma (RRMM) is complex, with several classes of drugs that can be combined into doublet, triplet, or quadruplet regimens. Real-world studies can help to determine the optimal treatment sequences and dosing through observed usage of drugs outside of clini...

Full description

Saved in:

Bibliographic Details
Main Authors:	Andrew Whiteley, Stephen C. Ijioma, David Ray, Spencer S. Langerman, Ellen Hu, Amy Pierre, Tomer Mark, Habte Yimer
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Series:	Current Oncology
Subjects:	real-world study relapsed/refractory multiple myeloma selinexor
Online Access:	https://www.mdpi.com/1718-7729/32/5/268
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Elotuzumab in the treatment of patients with refractory and relapsed multiple myeloma Experience of the Lapino Clinical Hospital Oncohematology Department
by: Yu. E. Ryabukhina, et al.
Published: (2023-12-01)

A case report of relapsed and refractory multiple myeloma with multifocal extramedullary infiltration and pulmonary adenocarcinoma
by: DU Fang, et al.
Published: (2025-01-01)

Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma
by: Carmen Tsang, et al.
Published: (2025-07-01)

Exploring what matters most to patients in relapsed refractory multiple myeloma treatment: a Canadian discrete choice experiment with patients, caregivers and physicians
by: Rebekah Hall, et al.
Published: (2025-07-01)

Treatment of double-refractory multiple myeloma
by: S. V. Semochkin
Published: (2021-09-01)

Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greater Gulf Region (REPAIR Study)
by: Ayman Alhejazi, et al.
Published: (2025-05-01)

Real‐World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1–3 Prior Lines of Therapy: Optum Database
by: Binod Dhakal, et al.
Published: (2025-08-01)

Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: a case series and literature review
by: Mei Zhou, et al.
Published: (2025-07-01)

Efficacy and safety of R-GemOx regimen for relapsed refractory B-cell lymphoma: a single-arm Meta analysis
by: Guo-Xin HUANG, et al.
Published: (2023-12-01)

Quantification of Total and Unbound Selinexor Concentrations in Human Plasma by a Fully Validated Liquid Chromatography-Tandem Mass Spectrometry Method
by: Suhyun Lee, et al.
Published: (2025-07-01)

Modern approaches to the treatment of relapsed follicular lymphoma
by: Yu. E. Ryabukhina, et al.
Published: (2022-07-01)

Efficacy and safety of mitoxantrone hydrochloride liposome-containing regimens in treating refractory/relapsed acute myeloid leukemia
by: Ni Lu, et al.
Published: (2025-05-01)

Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma—importance of pre-CAR-T optimization
by: Phoebe Joy Ho, et al.
Published: (2025-08-01)

FLAG with Bortezomib in Children and Adolescents with Relapsed/Refractory Acute Myeloid Leukemia in a Resource-Limited Setting: A Single-Center Experience from India
by: Dipesh Dave, et al.

X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL
by: Michela Carlet, et al.
Published: (2022-11-01)

Innovative evaluation of selinexor and JQ1 synergy in leukemia therapy via C-MYC inhibition
by: Pei-Hong Wang, et al.
Published: (2025-05-01)

Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies
by: Allison M. Bock, et al.
Published: (2025-07-01)

Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti‐CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma
by: Yian Zhang, et al.
Published: (2025-08-01)

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
by: Lina Zhang, et al.
Published: (2021-01-01)

CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis
by: Jing Shen, et al.
Published: (2025-08-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

Comparative clinical and economic assessment of polatuzumab vedotin therapy in combination with bendamustine and rituximab for adult transplantation-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma
by: I. N. Dyakov, et al.
Published: (2022-07-01)

Concurrent multiple myeloma and gastrointestinal amyloidosis presenting as chronic gastritis refractory to treatment
by: K. E. Chithrapathra, et al.
Published: (2025-08-01)

Case Report: Reactive T-cell large granular lymphocytes in the bone marrow of a patient with relapsed/refractory multiple myeloma receiving teclistamab
by: Erin A. Dean, et al.
Published: (2025-08-01)

Gilteritinib maintenance after allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia with FLT3-internal tandem duplication mutation
by: Chen Liang, et al.
Published: (2025-12-01)

CLINICAL CHARACTERISTICS AND TREATMENT RESULTS OF PEDIATRIC RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMAS
by: T. T. Valiev
Published: (2018-07-01)

Inotuzumab Ozogamicin as a Bridge to Stem Cell Transplantation in Relapsed Pediatric BCP‐ALL After Tisagenlecleucel: A Case Series
by: Margo Aertgeerts, et al.
Published: (2025-03-01)

Healthcare Costs and Treatment Patterns of Triplet Therapies in Relapsed/Refractory Multiple Myeloma: Real World Evidence from Italy
by: Perrone V, et al.
Published: (2025-07-01)

PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS
by: A. S. Kolbin, et al.
Published: (2017-05-01)

Results of Vincristine, Cyclophosphamide and Topotecan Protocol in Refractory/Relapsed Pediatric Solid Tumors: A Single-center Experience
by: Uğur Demirsoy, et al.
Published: (2019-09-01)

Factors Influencing Relapse After Omalizumab in Chronic Urticaria. Does the Method of Discontinuation Influence Relapse?
by: Petek Üstün, et al.
Published: (2025-07-01)

Pitfalls in the pathological diagnosis of multiple myeloma
by: V. V. Baykov
Published: (2022-11-01)

Elranatamab in Heavily Pretreated Triple-class Refractory Multiple Myeloma: A Single-center Experience
by: Ant Uzay
Published: (2025-08-01)

Cavenous Involvement in a Paint with Multiple Myeloma
by: Buket Tuğan Yıldız, et al.
Published: (2018-12-01)

Refractory Septic Shock (Part 2)
by: L. L. Plotkin
Published: (2021-07-01)

Imaging in plasma cell disorders—consensus recommendations of the Asian myeloma network bone imaging workgroup
by: Chandramouli Nagarajan, et al.
Published: (2025-06-01)

Research progress of the immunosuppressive tumor microenvironment in multiple myeloma
by: Yue WANG, et al.
Published: (2025-08-01)

Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML
by: Brian J. Ball, et al.
Published: (2025-07-01)

A study to identify novel biomarkers associated with multiple myeloma
by: Bhaskar Kalarani Iyshwarya, et al.
Published: (2023-11-01)